Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system

Background: Cholangiocarcinoma (CCA) is a highly lethal and aggressive epithelial tumor of the hepatobiliary system. A poor prognosis, propensity for relapse, low chance of cure and survival are some of its hallmarks. Pemigatinib, the first targeted treatment for CCA in the United States, has been d...

Full description

Bibliographic Details
Main Authors:	Ying Zhang, Li Ran, Yongchao Liang, Yanqiu Zhang, Zhuoling An
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Pharmacology
Subjects:	pemigatinib Food and Drug Administration adverse event reporting system disproportionality analysis real-word study Advers drug events
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1194545/full

Similar Items

Drug repositioning prediction for psoriasis using the adverse event reporting database
by: Minoh Ko, et al.
Published: (2023-03-01)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
by: Han N, et al.
Published: (2021-08-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022-04-01)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
by: Haoning Guo, et al.
Published: (2022-11-01)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024-02-01)

New Adverse Drug Reaction Signals from 2017 to 2021—Genuine Alerts or False Alarms?
by: Yoon Kong Loke, et al.
Published: (2024-02-01)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024-04-01)

Contrastive analysis on the safety of brand and generic nebivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system
by: Hongli Wang, et al.
Published: (2024-01-01)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023-04-01)

Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years
by: Julia E. Karrer, et al.
Published: (2019-06-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023-06-01)

ODAE: Ontology-based systematic representation and analysis of drug adverse events and its usage in study of adverse events given different patient age and disease conditions
by: Hong Yu, et al.
Published: (2019-05-01)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023-10-01)

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
by: Oleg Alekseev, et al.
Published: (2021-04-01)

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database
by: Hiroki Asano, et al.
Published: (2023-11-01)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
by: Christine Learned, BA, et al.
Published: (2022-06-01)

Role of the Clinical Pharmacist in Reducing Preventable Adverse Drug Events
by: Bahir A.Mshiemish
Published: (2017-02-01)

Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting System
by: Xerxes N Pundole, et al.
Published: (2019-07-01)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024-01-01)

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database
by: Madigan D, et al.
Published: (2018-04-01)

Opioids and frequency counts in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database: a quantitative view of the epidemic
by: Veronin MA, et al.
Published: (2019-08-01)

Adverse drug events caused by medication errors in medical inpatients
by: B Hardmeier, et al.
Published: (2004-11-01)

Detection of adverse drug events in e-prescribing and administrative health data: a validation study
by: Bettina Habib, et al.
Published: (2021-04-01)

A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19
by: Purva Patel, et al.
Published: (2023-03-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Adverse Events of DOACs in Children
by: Alessandra Bosch, et al.
Published: (2022-07-01)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
by: Xue-Feng Jiao, et al.
Published: (2023-01-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)

Prevalence rate of spontaneously reported adverse events and determinants of serious adverse events amongst three outpatient care settings in ghana: findings and implications
by: Israel Abebrese Sefah, et al.
Published: (2021-01-01)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
by: Jonathan Wadsley, et al.
Published: (2023-08-01)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases
by: Menglin He, et al.
Published: (2024-02-01)

Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports
by: Michael S. Ewer, et al.
Published: (2022-07-01)

Reporting of adverse events for marketed drugs: Need for strengthening safety database
by: Aditi Anand Apte
Published: (2016-01-01)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
by: Gennaro Gadaleta-Caldarola, et al.
Published: (2022-10-01)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
by: Jun Wang, et al.
Published: (2023-04-01)

Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database
by: LIANG Cuilyu, et al.
Published: (2022-11-01)

Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database
by: Jing Peng, et al.
Published: (2022-10-01)

The prevalence of adverse drug event-related admissions at a local hospital in Malaysia
by: Mahmathi Karuppannan, et al.
Published: (2013-01-01)